Diligence memo · auto-generated · as of July 3, 2026
Duo Oncology Inc.
Duo Oncology Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Duo Oncology Inc. operates in Pharmaceuticals, based in PITTSBURGH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Duo Oncology Inc. has raised $5.8M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.3M on 2023-01-31.
Most recent recorded round closed around 2025-06-02.
Valuation (modeled)modeled
Provath models Duo Oncology Inc. at approximately $1.4M (range $458K–$2.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.08× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 13 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 6.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 44% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.